TEHRAN (Tasnim) - A potential new drug showed promise in preclinical studies and provides hope for patients with advanced lung cancers. The investigational drug AZD9291, a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR ...